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This current issue of the BJA has a special focus on pain medicine and presents a mixture of invited 
reviews and original research across a broad range of pain related topics. Looking back to the last BJA  
pain special issue, in July 2013, there has been progress in our understanding of the problems and how 
to address them1. The challenge remains of translating these to clinical benefit, although there are steps 
in the right direction. In this editorial, we have tried to highlight some of the themes presented in this 
issue, within the context of current pain research.  
The Global Burden of Disease Collaboration (http://www.healthdata.org/gbd) is a unique initiative to 
improve our understanding of the epidemiology of disease, which is essential in order to develop 
effective, cohesive policies to improve healthcare and reduce inequities. The most recent analysis shows 
that chronic pain and mental health impose a major burden at a global level, with low back pain being 
the leading cause of globally of number of years lived with disability, followed by headache (above 
diabetes and COPD). This also does not fully take account of the hidden burden of pain within other 
chronic diseases, such as diabetes and rheumatoid arthritis 2-5. It is only in the latest update to the 
International Classification of Disease (ICD) that chronic pain is properly recognized and coded for6.  If 
used properly, this may be used to better inform future developments, although we do need to consider 
how best use this information to influence and implement effective pain management policies7, 8.  Mills 
et al in this issue, give a useful update of risk factors and demographic associations in chronic pain9. Risk 
factors may require a number of approaches to modify them, both at an individual and also, perhaps 
more importantly, at a population based l vel, through public health policy, in order to impact on long 
term outcomes. 
The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory and 
emotional experience, associated with actual or potential tissue damage, or described in terms of such 
damage”, and nociception as “The neural process of encoding noxious stimuli.” 10 One area where 
measurement of nociception, as a surrogate for pain may be useful, is in situations where 
communication is impaired (e.g under anaesthesia, critical care). For clinical utility, an objective measure 
of nociception would need to be reliable, consistently sensitive to analgesic interventions, and easy to 
use in different clinical situations.  The effect of nociception on autonomic function (e.g., heart rate, 
blood pressure, pupil diameter) has been utilised in a number of monitors to provide a way to guide 
analgesia, in areas where self-report and pain assessment is difficult. Several papers in this issue 
emphasizes the need for rigorous evaluation of such devices in relevant clinical settings before 
widespread use 11, 12. 
Whilst an objective approach to nociception may be possible, assessment and, subsequent management 
of pain remains subjective, and often suboptimal, even with the use of defined protocols and 
guidelines13. Education of healthcare staff and improved understanding of what factors affect clinical 
decision making around analgesia is explored using neuroimaging. Empathy and risk taking were shown 
to be some of the factors impacting on how patients with pain were managed in the emergency 
department 14. 
The management of patients with chronic non-malignant pain using long-term potent opioids has been 
the subject of much discussion, with concerns about increasing addiction and dependence rates, and the 
contribution that surgery may make to this problem 15, 16.  The IASP have produced a position statement 
around the use of opioids for chronic pain, which reflects these concerns, although ensuring continued, 
appropriate use of opioids in acute and cancer pain management is important, especially in lower and 






























































middle income countries 17, 18 The increasing number of patients presenting for surgery who are already 
on a strong opioid, create challenges for acute pain management 19. Buprenorphine, used for chronic 
pain and, increasingly, for opioid replacement therapy (ORT) for dependence is a partial agonist, with 
concerns about ceiling analgesic effects. There is a limited evidence base for how to manage acute pain 
in this patient group when they present for surgery, and for post-discharge analgesia 20, 21.  Using a 
Delphi approach clinical recommendations have been developed, with key recommendations to 
continue buprenorphine throughout the peri-operative period, with careful consideration of discharge 
planning22. The importance of continued review and assessment of all patients on strong opioids after 
surgery may be one way to reduce longer term problems 16.  
There has been a considerable amount of research on the progression of acute to chronic pain after 
surgery, with much greater understanding of this problem since it was first systematically studied, 
several decades ago23-25}. Interestingly research in this area for patients after critical care admission is 
identified as being much less advanced in the review by Kemp at al 26. The majority of studies in this area 
have not used pain specific questionnaires, but more general quality of life measures, where there 
hasn’t been a focus on persistent pain as a primary outcome, despite the fact that it may affect up to 
77% of survivors. Future studies should utilise pain specific outcome measures, with extended follow up 
periods. 
As we move forward we need to consider novel approaches to the development and evaluation of 
interventions for chronic pain. It is acknowledged that there are deficiencies in the standard 
Randomised Clinical Trial (RCT) approach to assessing chronic pain, with potential to either over 
estimate treatment effects, or to miss signals of efficacy and abandon potentially promising new 
therapies as a result27-29.   Different approaches to assessing novel analgesics, utilising biomarkers, may 
reduce required sample sizes, with increased sensitivity to detect signals of efficacy. The use of detailed 
sensory phenotyping is showing promise in predicting treatment efficacy or identifying individuals at 
increased risk of persistent pain, moving towards the holy grail of a personalized approach to pain 
medicine30-32. Neuroimaging, and other physiological measures may contribute to this, improving our 
understanding of pain perception, how it is modulated by expectation, and impact of the placebo effect, 
although further work needs to be done before translation to clinical use 33-37.   Understanding the 
molecular profile, aided by the use of large datasets such as the UKBiobank (www.ukbiobank.ac.uk/), is 
an additional important piece of the jigsaw that could improve clinical trial design, by accurate 
stratification of patients leading to individualisation of therapy 38.  
Whilst accurate stratification of patients is an important approach in assessing efficacy of novel 
analgesics, wider applicability needs to be assessed in a different way38. Pragmatic clinical trials can be 
used to ensure broad applicability to the wider patient population that is manged in routine clinical 
practice, rather than the carefully selected ones in RCTs. For example, many obstetric studies are limited 
to nulliparous women, A more pragmatic trial found that while programmed intermittent epidural bolus 
techniques are useful in obstetric analgesia, shorter, but more intense labour, in multiparous women 
may require a modification of the approach evidenced in RCTs 39. 
Our understanding of pain neurobiology advances, with novel pathways and targets identified for future 
improvement in analgesia. However, especially in chronic pain, despite major investment these by and 
large have not been translated into clinically useful treatments. Whilst not being unique to chronic pain, 
the problem is largely one of limitations in the internal and external validity of pre-clinical sciences 






























































approaches currently employed. 40-42 A number of potential novel targets are reported in this issue, with 
targets related to the inhibitory (e.g. GABA) / excitatory balance (NMDA)) well recognised as 
contributing to chronic pain states43, 44 45. In additional to laboratory and experimental pain models, 
being used to identify novel targets, the case report of an individual with a congenital insensitivity to 
pain illustrates how astute clinical observation can be used to help understand pain mechanisms.  In this 
case, the observation that minimal analgesia was required for a surgical procedure combined with a 
careful history resulted in further investigation of this individual and her family. Genotyping revealed the 
causative mutation in the Fatty Acid Amide Hydrolase pathway, reflected in corresponding 
abnormalities in the endogenous cannabinoid system, with high circulating levels of anandamide46.  It is 
refreshing that this serendipitous finding may be used to develop novel analgesics, emphasising the 
importance of a strong link between clinicians and academics. Not only is this essential in ensuring that 
research is relevant and important in the clinical setting, but it is a good illustration of how observations 
from the clinic can be used to drive and direct pain research.  It is however, important to emphasise that 
careful evaluation of any new agent is needed, with early clinical studies of FAAH not showing any 
benefit in osteoarthritis pain 47. There is ongoing interest in FAAH inhibitors as analgesics, but a precision 
medicine approach may be more suited to assessing these, and other novel interventions48-50 
So, in conclusion, has there been progress in the field of pain research over the last 6 years? While the 
steps may seem slow, there is no doubt that there is incremental progress, in a number of areas.   
Advances in Information Technology allow us to effectively interrogate large clinical datasets, to 
improve understanding at a population level, whilst improvements in our understanding of individual 
mechanisms may take us a step closer to personalised medicine in the field of chronic pain.  
Collaborations need to be supported, to bring together the diverse expertise that will be needed to take 
full advantage of these approaches. The traditional view of “translational pain medicine” as basic 
science to the clinic needs to be revaluated to reflect this. A further area that we must consider, is how 
we can address the problem at a global level, developing simple and effective solutions that can be used 
in resource poor areas.  New strategic funding opportunities such as those through the MRC-UK, and the 
Versus Arthritis  Research Roadmap for Pain  (see https://www.arthritisresearchuk.org/research/news-
and-updates-for-researchers/research-newsletter/april-2018/research-roadmap-for-pain.aspx) are to be 
welcomed, and perhaps, at last, reflect  a recognition of the public health challenge that is posed by 
chronic pain. It is with a feeling of optimism that we look forward to the future research developments 
that will be reported in the next Pain Special Issue of the BJA.
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